Pancreatic Cancer | Unmet Need | US/EU | 2019


Pancreatic cancer is a life-threatening disease with a survival rate of less than 10% and with no improvements in the last 40 years. Owing to the lack of rapid diagnostics, the disease quickly spreads to other parts of the body, resulting in a poor prognosis and limited treatment options. First-line treatment of metastatic pancreatic cancer is dominated by chemotherapeutic agents such as gemcitabine and Abraxane, with limited efficacy. Tarceva is the only targeted therapy approved for pancreatic cancer. This report presents a detailed analysis of the goals of pancreatic cancer treatment in the locally advanced and metastatic settings. We assess how current therapies perform on key drug attributes and measure the impact of drug attributes on physicians’ prescribing behavior. We also review which unmet needs novel therapies should address to distinguish themselves from their rivals and maximize uptake.


  • What are the treatment drivers and goals for locally advanced and metastatic pancreatic cancer?
  • What are the key influencers of treatment decisions and the hidden opportunities that developers could leverage?
  • How do current therapies, such as Ipsen / Servier’s Onivyde, Roche / Genentech’s Tarceva, and chemotherapy regimens, perform on key clinical drug attributes for this patient population?
  • What are the prevailing areas of unmet need and opportunity in locally advanced and metastatic pancreatic cancer?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European oncologists for a new treatment for first-line metastatic pancreatic cancer?


Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 30 European medical oncologists fielded in February 2019

Key companies: Eli Lilly, Genentech / Roche, Celgene, Merck, Ipsen / Servier

Key drugs: Gemcitabine, FOLFIRINOX, Capecitabine, Tarceva, Abraxane, Keytruda, Onivyde

Login to access report